Beovu Side Effects and Drug Safety Warnings: Severe Vision Loss, Blindness, Retinal Vasculitis Eye Inflammation
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
This Beovu timeline sets forth the still-developing story about why Beovu lawsuits might be filed against Novartis, the manufacturer of Beovu, alleging this drug company failed to adequately warn doctors and patients about Beovu side effects.
The points of interest included in this timeline are the discovery of Beovu side effects such as vision loss and blindness due to occlusive retinal vasculitis, retinal artery occlusion, and intraocular inflammation, the announcement of Beovu drug safety warnings by FDA, and more. This timeline will be kept up-to-date as we learn more about this Beovu drug injury situation.
The information on this web page is presented for general information purposes only, and not intended as a scientific authority or medical advice.
Beovu Approved by the FDA
October 7, 2019
Beovu is approved by the FDA to treat wet age-related macular degeneration.Read more
ASRS issue a note about Beovu related cases of retinal vasculitis
February 23, 2020
Chicago-based American Society of Retinal Specialists (ASRS) issued a note to members about 14 cases of retinal vasculitis across 46,000 injections since Beovu’s launch.Read more
Novartis claims current prescribing information documents are sufficient in risk analysis
March 2, 2020
Novartis stated the the current prescribing information document for its macular degeneration drug Beovu sufficiently addresses its risks of intraocular inflammation and retinal artery occlusion.Read more
Beovu label change revisions begin
April 9, 2020
Novartis said it would work with the FDA, the European Medicines Agency (EMA), and other drug safety regulators around the world to issue a revised Beovu drug label with new warning about Beovu vision-related side effects.Read more
Beovu Label Change Approved by the FDA
June 9, 2020
In early June 2020, the FDA approved a label update for Beovu whereby Novartis will add warnings and safety information about retinal vasculitis and retinal vascular occlusion, which can lead to loss of vision.Read more
Novartis Spokesman Gives Status Update on Beovu Safety Issues
August 4, 2020
In this four-minute video, a Novartis vice president discusses the company’s current approach to address Beovu safety issues relating to the occurrence of retinal vasculitis or retinal vascular occlusion associated with Beovu treatments.Read more
Beovu EU Label Change
September 14, 2020
Novartis updated the EU label to include retinal vasculitis and/or retinal vascular occlusion under “Special warnings and precautions for use” and “Undesirable effect”. The label notes that patients developing these events should discontinue treatment and the events should be promptly managed.Read more
We encourage you to submit a Beovu Case Evaluation Form online – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible drug injury case. Either way, you will get Mr. Lamb’s impressions – not an intake person, a paralegal, nor some other lawyer – about your case based on his many years of experience.